Peter Forsberg, MD
Hematology & Oncology · Denver, CONPI 1063656726
Payments from drug & device makers
Across 410 payments — averaging $13,505 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$4M
- Genentech, Inc.$955K
- Sanofi US Services Inc.$152K
- AbbVie$150K
- Karyopharm Therapeutics Inc.$113K
- Bristol Myers Squibb$73K
- plus $117K from 23 others
Across 4 payments — averaging $578.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$1K
- F. Hoffmann-la Roche AG$1K
- AbbVie$15
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 62 | $3,976,790 |
| Genentech, Inc. | 96 | $955,208 |
| Sanofi US Services Inc. | 27 | $151,992 |
| AbbVie | 49 | $149,717 |
| Karyopharm Therapeutics Inc. | 12 | $113,499 |
| Bristol Myers Squibb | 50 | $73,055 |
| Sanofi | 20 | $29,386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $28,713 |
| Pfizer | 11 | $12,352 |
| Gilead | 11 | $10,905 |
| E.r. Squibb & Sons, L.L.C. | 5 | $8,370 |
| Johnson & Johnson | 22 | $7,059 |
| Beone Medicines USA, Inc. | 2 | $4,031 |
| Sanofi-aventis U.S. LLC | 4 | $3,702 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $2,849 |
| Janssen Scientific Affairs, LLC | 6 | $2,828 |
| Legend Biotech USA Inc. | 2 | $2,781 |
| Genentech USA, Inc. | 3 | $2,026 |
| GSK | 2 | $1,319 |
| Amgen | 1 | $86 |
| Sobi, Inc | 2 | $54 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Secura Bio, Inc. | 1 | $43 |
| Incyte Corporation | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
How this compares
$5,536,965 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Allen CohnDenver$13.5M
- Robert RifkinDenver$11.3M
- Henning SchadeDenver$9M
- Jeffrey MatousDenver$8.4M
- Tara GregoryDenver$3.5M
- Mabel MardonesDenver$3M
- Amy SchmidtDenver$2.8M
- Michael TeesDenver$2.7M
- Yousuf GaffarDenver$1.8M
- Michael MarisDenver$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.